GHGuardant Health, Inc.
$151.30+64% 1Y
$151.30
$78.6052 weeks$187.33
Operating metrics
Oncology tests at Guardant Health: 117K for Q3 2026, +58% on a year ago.
Operating metrics
From earnings releases, Q3 2021 to Q3 2026
Oncology tests, Q3 2026+58% on a year ago117K
+58% on a year ago
Shield tests83,000
Q3 2026, +246% on a year ago
Oncology tests, Q3 2026: 117K
“Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58%”
Source: Q3 2026 earnings release, filed Nov 5, 2026Every quarter, with its source
| Quarter | Oncology tests | Shield tests | Release |
|---|---|---|---|
| Q3 2026 | 117K | 83,000 | Filed Nov 5, 2026 |
| Q2 2026 | 104K | 66,000 | Filed Jul 30, 2026 |
| Q1 2026 | 86,000 | 44,000 | Filed May 7, 2026 |
| Q4 2025 | 79,000 | 38,000 | Filed Feb 19, 2026 |
| Q3 2025 | 74,000 | 24,000 | Filed Oct 29, 2025 |
| Q2 2025 | 64,000 | 16,000 | Filed Jul 30, 2025 |
| Q1 2025 | 59,000 | 9,000 | Filed Apr 30, 2025 |
| Q4 2024 | 57,300 | 6,400 | Filed Feb 20, 2025 |
| Q3 2024 | 53,100 | n/a | Filed Nov 6, 2024 |
| Q2 2024 | 49,400 | n/a | Filed Aug 7, 2024 |
| Q1 2024 | 46,900 | n/a | Filed May 9, 2024 |
| Q4 2023 | 46,400 | n/a | Filed Feb 22, 2024 |
| Q3 2023 | 43,900 | n/a | Filed Nov 6, 2023 |
| Q2 2023 | 43,500 | n/a | Filed Aug 3, 2023 |
| Q1 2023 | 39,100 | n/a | Filed May 9, 2023 |
| Q4 2022 | 36,000 | n/a | Filed Feb 23, 2023 |
| Q3 2022 | 32,400 | n/a | Filed Nov 3, 2022 |
| Q2 2022 | 29,300 | n/a | Filed Aug 4, 2022 |
| Q1 2022 | 27,100 | n/a | Filed May 5, 2022 |
| Q4 2021 | 25,600 | n/a | Filed Feb 23, 2022 |
| Q3 2021 | 22,806 | n/a | Filed Nov 4, 2021 |
- Oncology tests
- Oncology (formerly called clinical) tests reported to customers in the quarter, excluding Shield screening tests.
- Shield tests
- Shield blood-based colorectal cancer screening tests reported in the quarter.
Source: company earnings releases furnished to the SEC on Form 8-K (Item 2.02, Exhibit 99), SEC EDGAR.
Diagnostics & Research
The closest names by size in the same industry